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A synthetic form of human pancreatic growth hormone releasing factor (GRF-44-NHz) was shown to be 
a potent stimulator of growth hormone (GH) secretion and cellular cyclic AMP levels in cultured sheep 
pituitary cells. A small dose-dependent stimulation of prolactin secretion was also observed. Somatostatin 
(0.5 PM) completely blocked the maximal GRF (1 nM)-stimulated secretion without a significant effect on 
cyclic AMP levels. Dopamine (0.1 PM) inhibited the GRF-elevated GH secretion by 50% and lowered 
cyclic AMP levels by 3OYo. Dopamine (0.1 PM) inhibition of basal prolactin secretion was not affected 
by GRF (1 nM). The data support the hypothesis that cyclic AMP is involved in the action of GRF but 
suggest hat somatostatin can inhibit GRF-induced secretion of GH independently of cyclic AMP. 
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1. INTRODUCTION 
Secretion of GH by the anterior pituitary gland 
is under the control of stimulatory and inhibitory 
factors produced by the hypothalamus. The major 
inhibitory factor, somatostatin, has been shown to 
exist in at least two active forms [l], SRIF-14 and 
the N-terminally extended SRIF-28. Two releasing 
factors (GRFs) have been isolated and characteris- 
ed from human pancreatic islet cell tumours [2,3]. 
The larger and more potent of these peptides (44 
residues) has been shown to be chromatographical- 
ly similar to a partially purified rat hypothalamic 
GRF. Both rat and human GRFs stimulated GH 
secretion in vitro by cultured rat pituitary cell 
Abbreviations: GRF, growth hormone releasing factor; 
SRIF, somatostatin; DA, dopamine; GH, growth hor- 
mone; VIP, vasoactive intestinal peptide; Hepes, 
N-2-hydroxyethylpiperazine-N’-Zethanesulfonic acid 
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monolayers and the dose-response curves were 
parallel [2]. A rat hypothalamic GRF has recently 
been more fully characterised; it shows 67% 
homology with human GRF (44-NH2) and has very 
similar effects in the rat pituitary cell monolayer 
system [4]. 
We describe here the effects of the most potent 
ectopic human GRF, the 44-NH2 residue polypep- 
tide, on sheep anterior pituitary cells in primary 
culture. We previously observed that both SRIF 
and DA can inhibit GH and prolactin secretion 
from sheep pituitary cells stimulated by the 
phosphodiesterase inhibitor isobutylmethylxan- 
thine [5] and we have therefore investigated also 
the effects of these inhibitory hypothalamic factors 
on secretion induced by the more specific 
secretagogue, GRF. 
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2. MATERIALS AND METHODS 
2.1. materials 
Synthetic GRF (44-NHz) and SRIF were obtain- 
ed from Universal Biologicals, Cambridge. DA 
was purchased from Sigma, Poole. Sera and 
culture media were obtained from Gibco, Paisley. 
Ovine GH (NIH-GH-S9; 0.56 IUlmg) and ovine 
prolactin (NIAMDD-oPRL- 14; 3 1 .O IUlmg) were 
gifts from Dr A.E. Wilhelmi and the National In- 
stitute of Arthritis, Diabetes and Digestive and 
Kidney Diseases, NIH, Bethesda. 
2.2. Preparation and culture of pituitary cells 
Cells were prepared and incubated as in [6]. 
Ovine anterior pituitary cells were dispersed (90 
min, 37’C) using collagenase (Boehringer, 1.5 
mgiml), hyaluronidase (Sigma-type Is, 0.5 
mg/ml), deoxyribonuclease I (Boehringer, grade 
II; 0.25 mg/ml) and bovine serum aIbumin (Sigma 
fraction V; 30 mglml) in medium containin NaCl 
(137 mM), KC1 (5 mM), Na2HP04 (0.7 mM), 
glucose (10 mM) and Hepes (25 mM), which was 
adjusted to pH 7.4 with NaOH. Cells were col- 
lected by centrifugation (400x g for 2 min) and 
washed 5 times by resuspension in the Hepes- 
buffered medium and ce~trifugation. The cells 
were pipetted (0.5-1.5 x lo6 cells/dish) into 3.5~cm 
culture plates (Sterilin), and incubated in Dulbec- 
co’s modified Eagle medium (3 ml/dish) contain- 
ing 25 mM Hepes, 5% foetal calf serum, 10% 
horse serum and antibiotics for 72 h at 37°C under 
95% air/50lo CO2. 
2.3. Experimental incubations 
After 72 h the incubation media were discarded 
and the cells were washed 3 times with the incuba- 
tion medium without serum. The cells were prein- 
cubated for 30 min, and then the media were 
replaced and experimental incubations were in- 
itiated by the addition of test substances. At the 
end of a further 30 min incubation the media were 
centrifuged (400 x g, 2 min), and the supernatants 
stored at -20°C until assayed for hormone con- 
tent. The cellular cyclic nucleotides were extracted 
with trichloroacetic acid [lO%(w/v) 2 h at 4”Cl 
and stored frozen at -2O”C, prior to assay. 
2.4. Assays 
The radioimmunoassay procedures for both 
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ovine GH and prolactin were based on methods us- 
ing specific antisera for these hormones raised in 
rabbits as in [6]. The cross-reactivities of prolactin 
and GH in these assays were less than 1%. Hor- 
mones were iodinated with NA1251 using a 
modification of the method in [7] as in [6]. All 
samples, standards etc. were dissolved in assay 
buffer containing sodium phosphate (0.05 M), pH 
7.6, merthiolate (0.6 mM), bovine serum albumin 
(O.OSYo) and Triton X-100 (0.05%). Cellular cyclic 
AMP samples were acetylated and measured as in 
181. 
3. RESULTS 
3.1.. Effect of GRF on secretion of GH and 
prolactin 
The effects of various GRF concentrations on 
GH and prolactin secretion after 30 min are shown 
in fig.1. GH secretion was maximally stimulated 
by 1 nM GRF to nearly 4-times the basal secretion 
level. The lowest dose of GRF tested (1 PM) 
stimulated GH secretion by 50%. Half-maximal 
stimulation occurred at about 8 pM. The effect of 
1 nM GRF on GH secretion was significant at the 
earliest time tested, 2 min (50% stimulation, 
p<O.Ol ). GRF also produced a small but signifi- 
cant dose-dependent stimulation of prolactin 
secretion, to 20-2507b over the basal level at 1 nM, 
GRF. 
3.2. Effect of GRF on cellular cyclic nuc~eotide 
concentrations 
GRF stimulated cellular cyclic AMP concentra- 
tions in a dose-dependent manner with a signifi- 
cant 2.5-fold increase at 10 pM GRF after 30 min. 
A maximal IO-la-fold stimulation was achieved at 
1 nM GRF (fig.1). Cyclic AMP concentrations 
were significantly elevated (4-fold) by 1 nM GRF 
at 2 min. There was no significant change detected 
in basal cyclic GMP cellular content at any GRF 
dose tested (not shown). 
3.3. 7;#re ffects of somatostat~n a d dopami~e 
on GRF-stimulated hormone secretions 
SRIF (0.5 PM) completely blocked the 5-fold 
stimulation of GH secretion induced by 1 nM 
GRF. SRIF alone inhibited basal GH secretion by 
30% (fig.2). DA (0.1 frM) partially inhibited the ef- 
fect of GRF by 50% but had no significant effect 













Fig. 1. Dose-response relationships for GRF stimulation 
of GH secretion (top), prolactin secretion (middle) and 
on basal GH secretion (fig.2). On the other hand, 
the stimulation of prolactin secretion by GRF was 
completely blocked by both DA and SRIF. DA 
alone inhibited basal prolactin secretion by 40% 
whilst SRIF had no significant effect (fig.2). 
3.4. Effects of somatostatin and dopamine on 
GRF-elevated cyclic AMP concentrations 
SRIF had no significant effect on the S-fold in- 
crease in cellular cyclic AMP content induced by 
GRF (fig.2). DA inhibited the effect of GRF on 
cyclic AMP concentrations by a third (fig.2). SRIF 
and DA both showed small (25%) inhibitions of 
basal cyclic AMP levels but only the effect of SRIF 
was statistically significant. 
4. DISCUSSION 
Our data demonstrate that the human pancreatic 
tumour-derived GRF (44-NH2) has a rapid and po- 
tent stimulatory effect on release of GH from 
cultured sheep pituitary cells. Half-maximal 
stimulation of GH secretion occurred at a concen- 
tration of 8 pM GRF, close to that found in studies 
using cultured rat pituitary cells (15 pM [2,9]). The 
rapid rise in secretory activity observed following 
addition of GRF to sheep pituitary cells in vitro is 
consistent with the time course reported for 
stimulation of GH secretion from perifused rat 
cells [9] and a study of secretion in the anaesthetis- 
ed rat [lo]. These results suggest hat a molecule 
similar to the human GRF may be involved in the 
physiological regulation of GH secretion in the 
sheep. 
It has been reported previously that GRF had no 
effect on prolactin secretion in vitro [2], though a 
small effect has been observed [9]. We observed a 
significant effect on prolactin secretion but only at 
a concentration of GRF (100 PM) lOO-fold greater 
than the minimum required to stimulate GH secre- 
tion. This apparent lack of specificity might be due 
cellular cyclic AMP levels (bottom). Sheep ituitary cells 
were cultured for 3 days then exposed to GRF at the 
concentrations indicated for 30 min. For each treatment 
the values for hormone released and cyclic AMP content 
represent the mean valueskSE/30 min per IO6 cells 
obtained from 5 replicate dishes. Control and 
experimental (+GRF) values were compared for 
statistical differences by Student’s f-test. Probability 
values: *p<O.OS, **p<O.Ol. 
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Fig.2. Effects of GRF (1 nM), SRIF (0.5 PM) and DA 
(0.1 PM) on GH secretion (top), prolactin secretion 
(middle) and cellular cyclic AMP content (bottom). The 
to the presence of a few GRF receptors on lac- 
totrophs. Alternatively, since GRF has been shown 
to interact with VIP receptors [ 111, it is possible 
that the stimulatory effect may be mediated via 
such receptors located on pituitary lactotrophs 
(VIP and GRF are homologous peptides). Other 
explanations are also possible. 
GRF-stimulated GH secretion was completely 
blocked by SRIF but only partially inhibited by 
DA, while the stimulation of prolactin secretion 
was reversed by both DA and SRIF. These results 
accord with our earlier work showing that DA in- 
hibited isobutylmethylxanthine-stimulated GH 
secretion from sheep pituitary cells [5] and suggest 
that somatotrophs may possess inhibitory DA 
receptors. On the other hand, DA inhibition of 
GRF-stimulated GH secretion was not seen in the 
rat [12]. Whether this represents a species dif- 
ference or the fact that a crude tumour medium 
which contained GRF was used in the experiments 
on rat pituitaries remains to be determined. Our 
finding that SRIF inhibited GRF-induced prolac 
tin secretion from sheep pituitary cells is consistent 
with recent reports that SRIF inhibits prolactin 
secretion stimulated by thyrotropin releasing fac- 
tor and VIP in the rat [13,14]. 
The rapid and extensive elevation of cellular 
cyclic AMP concentrations induced by GRF coin- 
cided with the increase in secretory activity. This 
supports the concept [15] that cyclic AMP is in- 
volved in mediating intracellularly the response to 
the releasing factor. Inhibition of GRF-stimulated 
GH secretion by SRIF appeared to be independent 
of the changes in cyclic AMP induced by GRF 
(fig.2), which suggests that the major site of action 
of SRIF is beyond cyclic AMP production, as con- 
cluded previously [ 15,161. These findings differ 
from those of authors in [17] who showed a dose- 
related inhibition of GRF-stimulated cyclic AMP 
levels by SRIF using rat pituitary cells and an in- 
cubation period of 3 h. One possible reason for 
histograms represent mean valueskSE/30 min per lo6 
cells. Data were combined from 5 experiments each 
using 4 dishes of cells per treatment and values were 
compared for significant differences by Student’s t-test. 
Significance levels: *p<O.O5, **~p<O.OOl compared 
with the appropriate controls; l **p<O.OOl compared 
with GRF alone. DA solv: control in which the 
antioxidant buffer used to dissolve DA (61 was added to 
the incubation. 
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this discrepancy may be that different incubation 
periods were used in the two studies. We found 
that GRF-induced cyclic AMP concentration 
reached a maximum within 15 min and then 
decreased, despite the continued presence of GRF. 
Effects of SRIF measured at 30 min and 3 h might 
well be expected to differ. It is possible therefore 
that the initial rapid stimulation of cyclic AMP by 
GRF is not blocked by SRIF while during prolong- 
ed exposure the lowering of stimulated cyclic AMP 
levels could become more important. A more 
detailed investigation of the time course for inhibi- 
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